Cipla, a global pharmaceutical company, and Kemwell Biopharma, a biopharmaceutical contract development and manufacturing organization (CDMO), have entered a joint venture agreement to develop, manufacture and commercialize biosimilars for global markets. A joint venture company will be incorporated with an aim to enter the respiratory biosimilars space.   The joint venture will leverage Cipla and Kemwell’s complementary strengths for end-to-end product development, clinical development, regulat...